Coherus BioSciences's Earnings: A Preview
Portfolio Pulse from Benzinga Insights
Coherus BioSciences (NASDAQ:CHRS) is set to release its latest quarterly earnings report on November 6, 2023. Analysts estimate an earnings per share (EPS) of $-0.31. The company's past performance shows a pattern of beating EPS estimates, which has often led to an increase in share price. However, the stock has been down 54.22% over the last 52-week period.
November 03, 2023 | 6:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Coherus BioSciences is expected to report an EPS of $-0.31. The company has a history of beating EPS estimates, which has often resulted in a share price increase. However, the stock has been down 54.22% over the last 52-week period.
The company's earnings report is a key event that could influence its stock price. While the company has a history of beating EPS estimates, which has often led to a share price increase, the overall trend for the stock has been negative over the past year. This suggests that while the earnings report could provide a short-term boost, there are likely other factors at play that are contributing to the stock's overall decline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100